Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05848206 · ClinicalTrials.gov registry record
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 251,831
- Enrollment target
NCT05848206 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 251,831 participants.
The verdict
NCT05848206 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 251,831 participants
- Enrollment target
Study Summary
This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251,831 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2022-04-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05848206
The ClinicalTrials.gov registry entry for NCT05848206 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 251,831 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05848206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05848206 about?
NCT05848206 is a clinical study titled "Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.". This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
What is the current status of trial NCT05848206?
This trial is currently completed. The enrollment target is 251,831 participants. The study started on 2022-03-11. Estimated completion is 2022-04-29.
Who is sponsoring clinical trial NCT05848206?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.